Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of surufatinib and tislelizumab in combination with concurrent chemoradiotherapy, followed by consolidation therapy with tislelizumab plus surufatinib, in patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).

NCT Number	NCT07086456
Lead Sponsor	Sun Yat-sen University
Conditions	Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy, Consolidation Therapy, Non-small Cell Lung Cancer
Enrollment	80 participants
Start Date	2025-07-20
Primary Completion	2029-07-19 (estimated)
Study Completion	2029-07-19 (estimated)
Updated on ClinicalTrials.gov	2025-07-25